DOCS
Mixed quarter, messy reaction
Doximity turned in a fourth-quarter report that looked a lot like a group project where one person did the slides and another dropped the ball. Sales climbed 5%, which is fine, but profitability headed the wrong way — and the stock got punished for it.
Why investors are bailing
For a company like Doximity, the market isn’t just asking, “Did you grow?” It’s asking, “Did you grow enough to justify the premium?” When margins wobble, the whole “future of digital healthcare” story gets a little less magical and a lot more spreadsheet-y.
The important bit
- Revenue growth was positive, but not exactly jaw-dropping
- Profitability declined, which is the part investors tend to fixate on when the stock is priced for perfection
- The selloff suggests Wall Street was expecting cleaner execution than what showed up in the numbers
Big picture: if you own DOCS, this is a reminder that even good-enough growth can get you tossed overboard when the market wants flawless.